share_log

United States Cellular Analyst Ratings

Benzinga ·  Jul 25, 2023 20:45
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
07/25/2023 52.37% Morgan Stanley $26 → $27 Maintains Equal-Weight
05/08/2023 -9.71% Wells Fargo $22 → $16 Maintains Underweight
02/07/2023 35.44% Morgan Stanley $37 → $24 Maintains Equal-Weight
01/10/2023 12.87% Wells Fargo $33 → $20 Downgrades Overweight → Underweight
11/08/2022 35.44% JP Morgan $32 → $24 Upgrades Underweight → Neutral
11/07/2022 Raymond James Downgrades Strong Buy → Market Perform
08/08/2022 120.09% Raymond James $41 → $39 Maintains Strong Buy
05/09/2022 131.38% Raymond James $40 → $41 Maintains Strong Buy
04/19/2022 108.8% Morgan Stanley → $37 Downgrades Overweight → Equal-Weight
02/22/2022 86.23% Wells Fargo $36 → $33 Maintains Overweight
02/22/2022 125.73% Raymond James $43 → $40 Maintains Strong Buy
08/02/2021 103.16% JP Morgan $35 → $36 Downgrades Neutral → Underweight
07/22/2021 182.17% Morgan Stanley $50.5 → $50 Maintains Overweight
02/22/2021 97.52% JP Morgan $42 → $35 Downgrades Overweight → Neutral
01/14/2021 184.99% Morgan Stanley $57 → $50.5 Maintains Overweight
11/16/2020 103.16% Wells Fargo → $36 Reinstates → Overweight
08/31/2020 159.59% Citigroup $45 → $46 Maintains Buy
08/27/2020 221.67% Morgan Stanley $56 → $57 Maintains Overweight
08/10/2020 142.66% Raymond James $40 → $43 Maintains Strong Buy
07/08/2020 216.03% Morgan Stanley $57 → $56 Maintains Overweight
05/18/2020 125.73% Raymond James $39 → $40 Reiterates → Strong Buy
05/14/2020 91.87% B. Riley Securities $42 → $34 Maintains Neutral
04/22/2020 120.09% Raymond James $41 → $39 Maintains Strong Buy
04/09/2020 221.67% Morgan Stanley $63 → $57 Maintains Overweight
03/27/2020 137.02% JP Morgan $45 → $42 Maintains Overweight
03/02/2020 255.53% Citigroup $66 → $63 Maintains Buy
11/04/2019 176.52% Raymond James $53 → $49 Upgrades Outperform → Strong Buy
11/04/2019 153.95% JP Morgan → $45 Upgrades Neutral → Overweight
08/06/2019 125.73% Wells Fargo $50 → $40 Maintains Market Perform
08/06/2019 137.02% B. Riley Securities $50 → $42 Maintains Neutral
08/05/2019 159.59% JP Morgan → $46 Upgrades Underweight → Neutral
06/18/2019 264% Morgan Stanley $44 → $64.5 Upgrades Equal-Weight → Overweight
05/06/2019 199.1% Raymond James $56 → $53 Reiterates → Outperform
11/06/2018 216.03% Raymond James $43 → $56 Maintains Outperform
08/08/2018 187.81% Citigroup $49 → $51 Maintains Buy

What is the target price for United States Cellular (USM)?

The latest price target for United States Cellular (NYSE: USM) was reported by Morgan Stanley on July 25, 2023. The analyst firm set a price target for $27.00 expecting USM to rise to within 12 months (a possible 52.37% upside). 7 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for United States Cellular (USM)?

The latest analyst rating for United States Cellular (NYSE: USM) was provided by Morgan Stanley, and United States Cellular maintained their equal-weight rating.

When is the next analyst rating going to be posted or updated for United States Cellular (USM)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of United States Cellular, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for United States Cellular was filed on July 25, 2023 so you should expect the next rating to be made available sometime around July 25, 2024.

Is the Analyst Rating United States Cellular (USM) correct?

While ratings are subjective and will change, the latest United States Cellular (USM) rating was a maintained with a price target of $26.00 to $27.00. The current price United States Cellular (USM) is trading at is $17.72, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment